ALT
NASDAQ · Biotechnology
Altimmune Inc
$1.97
-0.15 (-7.08%)
Open$2.12
Previous Close$2.12
Day High$2.13
Day Low$1.91
52W High$6.44
52W Low$2.00
Volume—
Avg Volume3.48M
Market Cap392.81M
P/E Ratio—
EPS$-0.78
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+435.5% upside
Current
$1.97
$1.97
Target
$10.55
$10.55
$6.68
$10.55 avg
$11.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 93.1K | 232.2K | 252.74M |
| Net Income | -186,146,809 | -932,514,656 | 22.15M |
| Profit Margin | -214,861.0% | -451,530.3% | 8.8% |
| EBITDA | -199,420,404 | -1,065,342,972 | 31.01M |
| Free Cash Flow | — | — | 16.83M |
| Rev Growth | — | -83.5% | +1.7% |
| Debt/Equity | 0.15 | — | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |